| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 3,042 | 3,812 | 3,410 | 3,137 | 3,312 | 3,581 | 3,699 | 3,717 | 3,510 | 3,584 | 4,102 | 3,887 | 3,536 | 4,016 | 4,081 | 3,985 | 4,366 | 3,973 | 4,365 | 4,307 | 4,395 | 4,342 | 5,026 | 5,241 | 4,645 | 5,536 | 5,547 | 5,534 | 5,288 | 5,421 | 5,882 | 5,845 | 5,801 | 6,406 | 6,766 | 6,690 | 6,332 | 6,785 | 7,152 | 7,183 | 6,887 | 7,096 | 7,716 |
| Expenses | 2,585 | 2,784 | 2,669 | 2,688 | 3,138 | 3,039 | 3,070 | 2,970 | 3,076 | 2,879 | 3,278 | 3,095 | 3,219 | 3,213 | 3,310 | 3,300 | 3,443 | 3,084 | 3,486 | 3,613 | 3,743 | 3,297 | 3,862 | 3,938 | 3,810 | 4,283 | 4,294 | 4,248 | 4,568 | 4,232 | 4,526 | 4,403 | 4,748 | 4,835 | 4,944 | 5,051 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 |
| EBITDA | 457 | 1,028 | 741 | 450 | 174 | 543 | 629 | 748 | 434 | 705 | 824 | 792 | 317 | 803 | 771 | 685 | 923 | 889 | 879 | 694 | 652 | 1,045 | 1,164 | 1,303 | 835 | 1,253 | 1,253 | 1,286 | 720 | 1,190 | 1,356 | 1,442 | 1,053 | 1,571 | 1,821 | 1,639 | 1,484 | 1,807 | 1,986 | 2,099 | 1,695 | 1,916 | 2,022 |
| Operating Profit % | 13 % | 26 % | 21 % | 12 % | 4 % | 15 % | 16 % | 17 % | 12 % | 16 % | 18 % | 19 % | 8 % | 16 % | 16 % | 16 % | 19 % | 21 % | 18 % | 15 % | 13 % | 23 % | 22 % | 24 % | 17 % | 22 % | 22 % | 22 % | 13 % | 20 % | 21 % | 23 % | 16 % | 23 % | 25 % | 22 % | 20 % | 25 % | 26 % | 27 % | 21 % | 24 % | 24 % |
| Depreciation | 136 | 149 | 158 | 177 | 270 | 204 | 229 | 258 | 632 | 213 | 302 | 522 | 285 | 241 | 282 | 293 | 510 | 268 | 283 | 278 | 346 | 269 | 265 | 248 | 285 | 261 | 253 | 248 | 290 | 254 | 299 | 272 | 346 | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 |
| Interest | 43 | 64 | 64 | 31 | 48 | 32 | 35 | 59 | 33 | 28 | 42 | 9 | 35 | 35 | 44 | 44 | 45 | 52 | 46 | 46 | 53 | 46 | 39 | 48 | 28 | 30 | 38 | 21 | 18 | 18 | 26 | 32 | 34 | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 |
| Profit Before Tax | 390 | 892 | 595 | 322 | -82 | 401 | 444 | 514 | -137 | 557 | 574 | 340 | 199 | 620 | 509 | 449 | 501 | 663 | 681 | 506 | 328 | 799 | 926 | 1,022 | 544 | 996 | 996 | 1,054 | 448 | 975 | 1,100 | 1,218 | 745 | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 |
| Tax | 106 | 242 | 43 | 54 | 5 | 57 | 74 | 129 | -74 | 132 | 139 | -63 | 46 | 175 | 142 | 127 | 144 | 216 | 207 | 167 | 89 | 233 | 266 | 270 | 132 | 286 | 287 | 297 | 77 | 268 | 303 | 410 | 224 | 377 | 439 | 405 | 327 | 436 | 484 | 342 | 290 | 478 | 500 |
| Net Profit | 284 | 650 | 552 | 269 | -87 | 344 | 370 | 385 | -63 | 425 | 435 | 404 | 153 | 446 | 367 | 322 | 358 | 447 | 475 | 339 | 239 | 566 | 659 | 752 | 412 | 710 | 709 | 757 | 371 | 706 | 797 | 808 | 522 | 998 | 1,155 | 1,068 | 932 | 1,176 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 |
| EPS in ₹ | 3.24 | 8.09 | 6.76 | 3.24 | -1.16 | 4.22 | 4.41 | 4.66 | -0.77 | 5.08 | 5.25 | 4.98 | 2.22 | 5.60 | 4.68 | 4.12 | 4.56 | 5.93 | 5.85 | 4.35 | 3.05 | 7.17 | 8.25 | 9.28 | 5.13 | 8.86 | 8.82 | 9.03 | 4.49 | 8.51 | 9.78 | 9.92 | 6.51 | 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.07 | 16.73 |
Cipla
Cipla
1,519.30
+4.40
(0.29%)
Key Fundamentals
Market Cap
1,22,366.70 Cr
EPS
65.29
PE Ratio
22.59
Dividend Yield
1.05 %
Industry
Healthcare 52 Week High
1,673.00
52 Week Low
1,335.00
PB Ratio
3.73
Debt to Equity
0.02
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from36 analysts
Actual
Company News
View All News
Mounjaro achieved the position of India's highest revenue-generating drug in October, recording monthly sales of ₹1 billion. Eli Lilly has partnered with Cipla for the drug's distribution across India.
Cipla delivered its highest-ever quarterly revenue of ₹7,589 crores with 8% year-on-year growth and maintained a robust EBITDA margin of 25%. The company announced Achin Gupta as the designated CEO, effective January 1st, taking full responsibilities from April 1st. One-India business showed improving growth at 7% year-on-year, with key therapies like anti-diabetes (10%), cardiac (13%), urology (17%), and dermatology (18%) delivering strong double-digit growth. The company added four new brands to the ₹100 crores plus club, bringing the total to 29 brands. In North America, Cipla emerged as the number one player in the U.S. albuterol MDI market with 22% market share and launched filgrastim, its first biosimilar. The company entered the obesity care segment through a partnership with Eli Lilly, launching Yurpeak (tirzepatide) in India. Cipla revised its full-year EBITDA margin guidance to 22.75%-24% from the earlier 23.5%-24.5%, primarily due to increased R&D investments of 7.1% of revenue and reduced contribution from generic Revlimid. The company maintains a strong net cash position of ₹9,901 crores.
Cipla Limited has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences Limited for INR 110.65 crores through a cash transaction. Inzpera, incorporated in 2016, develops, manufactures and markets differentiated paediatric pharmaceutical and wellness products. The company reported turnover of INR 26.75 crores in FY2024-25, INR 22.05 crores in FY2023-24, and INR 20.76 crores in FY2022-23. The enterprise value is INR 120 crores, with the purchase consideration adjusted for working capital. The acquisition aims to combine Inzpera's paediatric pharmaceutical portfolio with Cipla's distribution network and operational capabilities. The transaction is expected to be completed within one month from signing, making Inzpera a wholly owned subsidiary of Cipla.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,732.10 | #1 4,11,749.90 | 39.63 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 66.26 | |
6,520.00 | 1,73,603.20 | 69.64 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.59 | |
3,824.60 | 1,29,482.50 | 60.46 | 11,539.40 | 6.99 | 1,911 | 30.46 | 70.50 | |
1,519.30 | #4 1,22,366.70 | #5 22.59 | #4 28,409.50 | #8 7.12 | #3 5,291 | #7 3.71 | 44.46 | |
1,229.60 | 1,01,113.50 | #1 17.88 | 33,741.20 | 16.73 | 5,725 | -0.38 | 47.35 | |
951.40 | 94,475.30 | 19.03 | 23,511.00 | 18.55 | 4,615 | 34.60 | 39.39 | |
2,270.00 | 91,653.00 | 52.89 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.59 | |
2,033.90 | 90,250.10 | 21.39 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 62.84 | |
5,767.50 | 68,110.20 | 29.54 | 13,458.30 | 3.70 | 2,216 | 21.39 | 70.49 | |
1,183.60 | 67,849.20 | 20.35 | 32,345.60 | 9.43 | 3,484 | 3.81 | 67.18 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
7.12 %
Net Income Growth
27.33 %
Cash Flow Change
21.07 %
ROE
9.10 %
ROCE
2.32 %
EBITDA Margin (Avg.)
5.95 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 |
| Fixed Assets | 6,830 | 9,369 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,161 | 9,607 | 10,006 |
| Current Assets | 7,591 | 8,841 | 8,736 | 10,814 | 12,427 | 11,706 | 13,210 | 14,711 | 16,805 | 19,392 | 23,249 |
| Capital Work in Progress | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,566 |
| Investments | 390 | 758 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 |
| Other Assets | 7,917 | 8,940 | 8,889 | 10,670 | 11,125 | 11,684 | 11,957 | 14,101 | 15,547 | 16,509 | 17,882 |
| Total Liabilities | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 | 37,387 |
| Current Liabilities | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,110 | 5,246 | 5,484 |
| Non Current Liabilities | 854 | 1,486 | 4,682 | 4,447 | 4,848 | 3,212 | 1,975 | 1,071 | 640 | 670 | 614 |
| Total Equity | 10,982 | 11,866 | 12,982 | 14,582 | 15,344 | 16,057 | 18,586 | 21,117 | 23,714 | 26,802 | 31,289 |
| Reserve & Surplus | 10,629 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 31,032 |
| Share Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 389 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 | 30 |
| Investing Activities | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,983 | -3,682 |
| Operating Activities | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | 5,005 |
| Financing Activities | 165 | 3,104 | -1,326 | -386 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | -1,293 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 36.73 % | 36.72 % | 36.12 % | 36.11 % | 33.63 % | 33.61 % | 33.61 % | 33.61 % | 33.55 % | 33.47 % | 33.47 % | 33.47 % | 33.47 % | 30.91 % | 30.92 % | 29.19 % | 29.20 % | 29.19 % | 29.21 % |
| FIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 25.74 % | 25.73 % | 25.83 % | 27.81 % | 28.80 % | 26.65 % | 26.28 % | 25.25 % | 24.55 % |
| DIIs | 16.79 % | 15.91 % | 17.41 % | 17.61 % | 17.72 % | 17.12 % | 19.71 % | 21.13 % | 22.10 % | 24.34 % | 24.18 % | 24.33 % | 24.42 % | 24.95 % | 24.16 % | 27.71 % | 28.15 % | 29.26 % | 30.25 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 16.14 % | 16.01 % | 15.97 % | 15.55 % | 15.41 % | 14.83 % | 14.72 % | 14.85 % | 14.66 % | 14.45 % | 14.34 % | 14.20 % | 14.24 % | 14.16 % | 14.29 % | 14.13 % | 14.10 % | 13.82 % |
| Others | 30.23 % | 31.22 % | 30.47 % | 30.30 % | 33.10 % | 33.86 % | 31.84 % | 30.53 % | 29.50 % | 27.53 % | 2.16 % | 2.12 % | 2.08 % | 2.09 % | 1.95 % | 2.15 % | 2.23 % | 2.20 % | 2.16 % |
| No of Share Holders | 3,64,796 | 4,08,401 | 4,10,831 | 4,51,365 | 4,18,584 | 4,18,910 | 3,88,864 | 4,04,182 | 4,75,293 | 4,66,513 | 4,26,861 | 4,25,731 | 4,36,154 | 4,63,569 | 4,70,234 | 5,25,114 | 5,43,420 | 5,49,655 | 5,34,587 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2 | 3 | 3 | 4 | 5 | 5 | 8.5 | 13 | 16 |
| Dividend Yield (%) | 0.00 | 0.37 | 0.57 | 0.71 | 0.49 | 0.49 | 0.56 | 0.57 | 0.9 | 1.06 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 11 Aug 2021 |  Dividend | ₹ 5.00 /share | 09 Aug 2021 | 898.60 | 912.60 |
| 10 Aug 2022 | Dividend | ₹ 5.00 /share | 08 Aug 2022 | 937.55 | 1,029.55 |
| 26 Aug 2022 |  Annual General Meeting | NA | 26 Aug 2022 | 955.10 | 1,025.45 |
| 21 Jul 2023 | Dividend | ₹ 8.50 /share | 21 Jul 2023 | 943.95 | 1,056.20 |
| 02 Aug 2024 | Dividend | ₹ 13.00 /share | 02 Aug 2024 | 1,358.80 | 1,546.15 |
| 20 Aug 2024 | Annual General Meeting | NA | 20 Aug 2024 | 1,358.80 | 1,575.50 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 1,654.10 | 1,503.50 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 1,510.25 | 1,396.10 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,415.55 | 1,512.00 |
| 27 Jun 2025 | Dividend | ₹ 3.00 /share | 27 Jun 2025 | 1,512.00 | 1,513.80 |
| 27 Jun 2025 | Dividend | ₹ 13.00 /share | 27 Jun 2025 | 1,512.00 | 1,513.80 |
| 16 Jul 2025 | Annual General Meeting | NA | 16 Jul 2025 | 1,512.00 | 1,490.90 |
| 25 Jul 2025 | Quarterly Result Announcement | NA | 25 Jul 2025 | 1,505.90 | 1,487.90 |
| 30 Oct 2025 | Quarterly Result Announcement | NA | 30 Oct 2025 | 1,527.90 | 1,580.75 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Acquisition9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
Oct 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 30, 2025
Oct 30, 2025Outcome Of Board Meeting Dated 30Th October 2025Oct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationOct 30, 2025
Oct 30, 2025Board Meeting Outcome for Financial Results For Quarter And Half Year Ended 30Th September 2025
Oct 30, 2025
Oct 30, 2025Financial Results For Quarter And Half Year Ended 30Th September 2025Oct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 23, 2025
Oct 23, 2025Product Launch - Lilly And Cipla Sign Marketing And Distribution Agreement For Second Brand Of Tirzepatide In IndiaOct 23, 2025
Oct 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 19, 2025
Oct 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 13, 2025
Oct 13, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday 30Th October 2025.Sep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 12, 2025
Sep 12, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Aug 19, 2025Intimation Of Cancellation Of Schedule Of Analyst / Institutional Investor MeetingsAug 13, 2025
Aug 13, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 11, 2025
Aug 11, 2025Update On USFDA Inspection At Companys Manufacturing Facility In Bommasandra Bengaluru IndiaAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 02, 2025
Aug 02, 2025Clarification On The News Item Dated 1St August 2025 Titled Pharma Stocks Slump As Trump Shoots Letters To 17 Global Drug Majors Seeking Lower Prices Appearing In Www.Moneycontrol.ComAug 01, 2025
Aug 01, 2025Clarification sought from Cipla LtdAug 01, 2025
Aug 01, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 27, 2025
Jul 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 25, 2025
Jul 25, 2025Grant Of Esops/EsarsJul 25, 2025
Jul 25, 2025Board Meeting Outcome for Financial Results For Quarter Ended 30Th June 2025Jul 25, 2025
Jul 25, 2025Financial Results For Quarter Ended 30Th June 2025Jul 25, 2025
Jul 25, 2025Transcript Of The 89Th Annual General MeetingJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 21, 2025
Jul 21, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 16, 2025
Jul 16, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 12, 2025
Jul 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Board Meeting Intimation for Quarter Ended 30Th June 2025 Under SEBI Listing RegulationsJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Mutual Fund Holdings
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
DSP ELSS Tax Saver Fund Direct Plan-Growth 
Axis Large Cap Fund Direct-Growth 
Quant ELSS Tax Saver Fund Direct-Growth 
UTI Large Cap Fund Direct-Growth 
Parag Parikh Flexi Cap Fund Direct-Growth 
HDFC Innovation Fund Direct-Growth 
HDFC Pharma And Healthcare Fund Direct - Growth 
NJ Balanced Advantage Fund Direct - Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth 
Mirae Asset Healthcare Fund Direct - Growth 
Bajaj Finserv Balanced Advantage Fund Direct-Growth 
Canara Robeco Large Cap Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 42.33
ATR(14)
Less Volatile 29.86
STOCH(9,6)
Oversold 10.54
STOCH RSI(14)
Oversold 5.28
MACD(12,26)
Bearish -9.75
ADX(14)
Weak Trend 19.07
UO(9)
Bearish 42.08
ROC(12)
Downtrend And Accelerating -9.14
WillR(14)
Oversold -88.40
About Cipla
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Website
Chairperson NameY K Hamied
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
